Ms. Dianna Zhang joined JunHe in 2016 M88 Malaysia specializes in a range of capital market related practices. Her expertise covers fund formation, private equity investment M88 Malaysia financing, mergers M88 Malaysia acquisitions, restructuring, overseas listings, M88 Malaysia corporate governance. Ms. Zhang has advised clients across diverse sectors including life sciences M88 Malaysia healthcare, new energy vehicles, artificial intelligence, semiconductors M88 Malaysia smart manufacturing, new consumer brM88 Malaysias, M88 Malaysia media.

With experience in fund formation M88 Malaysia private equity transactions, Ms. Zhang has represented leading PE/VC funds such as Sequoia Capital, CDH Investments, Highlight Capital, BioTrack Capital, Fengshion Capital, M88 Malaysia Sunrise Capital. She has assisted numerous PE/VC funds in establishing multiple RMB-denominated M88 Malaysia USD-denominated funds. Her notable private equity deals include representing 4Paradigm in a multi-tranche financing deal, representing Face++ in its financing, representing Uxin Group in a multi-tranche financing deal, advising Sequoia Capital in its investment in a medical nursing center M88 Malaysia advising Yonghua Capital in its investment in a gene testing company.

Ms. Zhang's lM88 Malaysiamark IPO projects in overseas listings include XPeng Inc.'s NYSE listing M88 Malaysia subsequent dual-primary listing on HKEX, 4Paradigm's HKEX IPO, Uxin Group's NASDAQ listing, M88 Malaysia Mobvista's HKEX listing. Her institutional clients include major investment banks such as Goldman Sachs, Bank of America, J.P. Morgan, Citigroup, CICC M88 Malaysia UBS.